• 1. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 2. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565

• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides
• Solvents and Organic Chemicals Organic Compounds

Recent Advances in the Study of 2-(1H-Pyrazol-1-yl)aniline (CAS: 54705-91-8) in Chemical Biology and Pharmaceutical Research

The compound 2-(1H-Pyrazol-1-yl)aniline (CAS: 54705-91-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This heterocyclic amine, characterized by a pyrazole ring linked to an aniline moiety, serves as a key intermediate in the synthesis of various bioactive molecules. Recent studies have highlighted its potential as a scaffold for designing novel kinase inhibitors, antimicrobial agents, and anti-inflammatory compounds, making it a focal point for interdisciplinary research.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 2-(1H-Pyrazol-1-yl)aniline derivatives as selective inhibitors of JAK2 kinases, which are implicated in myeloproliferative disorders. The research team utilized structure-activity relationship (SAR) analysis to optimize the compound's binding affinity, achieving nanomolar potency against JAK2 while minimizing off-target effects. These findings underscore the compound's potential as a lead candidate for targeted cancer therapies, particularly in hematological malignancies.

In the realm of antimicrobial research, a breakthrough study in Bioorganic & Medicinal Chemistry Letters (2024) reported that 2-(1H-Pyrazol-1-yl)aniline-based compounds exhibited broad-spectrum activity against drug-resistant bacterial strains, including MRSA and ESBL-producing E. coli. The mechanism of action was attributed to disruption of bacterial cell membrane integrity and inhibition of efflux pumps, addressing two critical challenges in antibiotic development. This dual mechanism positions these derivatives as promising candidates for combating antimicrobial resistance (AMR), a global health priority.

Recent advancements in synthetic methodologies have also expanded the accessibility of 2-(1H-Pyrazol-1-yl)aniline derivatives. A 2024 Organic Process Research & Development paper detailed a novel continuous-flow synthesis approach that improved yield (82% vs. traditional batch's 65%) while reducing hazardous waste generation by 40%. This green chemistry innovation addresses both scalability and sustainability concerns in pharmaceutical manufacturing, potentially accelerating the translation of research findings into clinical applications.

The compound's unique electronic properties have enabled its application in materials science as well. Research published in ACS Applied Materials & Interfaces (2023) demonstrated that 2-(1H-Pyrazol-1-yl)aniline derivatives can serve as efficient organic semiconductors in biosensor development. These sensors showed remarkable sensitivity in detecting biomarkers for neurodegenerative diseases, opening new avenues for diagnostic tool development.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic properties of 2-(1H-Pyrazol-1-yl)aniline-based drugs. Recent ADMET studies (2024) have identified metabolic stability as a key area requiring improvement, particularly for oral administration routes. Several research groups are currently exploring prodrug strategies and formulation technologies to enhance bioavailability while maintaining the compound's therapeutic efficacy.

In conclusion, 2-(1H-Pyrazol-1-yl)aniline (CAS: 54705-91-8) continues to emerge as a multifaceted building block in pharmaceutical research, with applications spanning from targeted therapies to diagnostic tools. The convergence of recent synthetic innovations, biological insights, and material science applications positions this compound as a valuable asset in addressing current healthcare challenges. Future research directions likely include further optimization of drug-like properties and exploration of combination therapies leveraging its unique chemical features.

• 17635-45-9(4-(1H-Pyrazol-1-yl)aniline)
• 62572-62-7(Nickel, bis[2-(1H-pyrazol-1-yl)phenyl]-)
• 62572-61-6(Cobalt, tris[2-(1H-pyrazol-1-yl)phenyl]-)
• 62572-60-5(Chromium, tris[2-(1H-pyrazol-1-yl)phenyl]-)
• 359014-72-5(Tris(2-(1H-pyrazol-1-yl)phenyl)iridium)
• 184097-88-9(3-(1H-Pyrazol-1-yl)aniline)
• 1126-00-7(1-Phenylpyrazole)
• 62568-09-6(Vanadium, tris[2-(1H-pyrazol-1-yl)phenyl]-)
• 62568-08-5(Titanium, tris[2-(1H-pyrazol-1-yl)phenyl]-)
• 62613-19-8(Magnesium, chloro[2-(1H-pyrazol-1-yl)phenyl]-)